following an abbreviated submission:
empagliflozin/metformin (Synjardy®) is accepted for restricted use within NHS Scotland.
Indication under review: in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control;
• in patients inadequately controlled on their maximally tolerated dose of metformin alone
• in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin
• in patients already being treated with the combination of empagliflozin and metformin as separate tablets.
SMC restriction:
• for use in patients for whom this fixed dose combination of empagliflozin and metformin is considered appropriate.
• for use as dual therapy (empagliflozin and metformin) when a sulphonylurea is inappropriate.
Empagliflozin/metformin (Synjardy®) has the potential to reduce the pill burden at no additional cost.
Download detailed advice112KB (PDF)
Medicine details
- Medicine name:
- empagliflozin/metformin (Synjardy)
- SMC ID:
- 1092/15
- Indication:
- in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control / in patients inadequately controlled on their maximally tolerated dose of metformin alone / in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin / in patients already being treated with the combination of empagliflozin and metformin as separate tablets.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 12 October 2015